Steelers defensive end Yahya Black is putting AAMDSIF in the spotlight—add your support with a gift today.
Aged individuals with somatic TP53 mutations manifest clonal hematopoiesis (CH) and are at high risk of developing myeloid neoplasms. However, the underlying mechanisms are not fully understood. Here we show that inflammatory stress confers a competitive advantage to p53 mutant…
Abstract NRAS and KRAS mutations, commonly identified alongside ancestral co-mutations, are generally regarded as pathogenic in adults presenting with monocytosis and/or cytopenia(s). However, their significance in isolation is not well defined. We studied a multi-institutional…
Chemotherapy-free approaches could offer comparable efficacy with less toxicity (ORLANDO, Dec. 7, 2025) — Targeted therapies and immunotherapies are increasingly offering viable alternatives to the chemotherapies that have stood for decades as a mainstay of treatment for…
Dr. Lin received her undergraduate degree from the University of Virginia and her MD from the Medical College of Virginia/Virginia Commonwealth University. She earned a Master of Science degree in Clinical Research from Tulane University. She completed Internal Medicine residency at the University of Maryland and Medical Oncology Fellowship at Johns Hopkins. She then completed a post-doctoral fellowship at UCLA in the laboratory of Dr. Kathleen Sakamoto with a focus on leukemia stem cells. She served on the faculty in Hematology/Oncology at the Louisiana State University Health Sciences Center
This guide provides important information about bone marrow and stem cell transplantation
This guide provides information about clinical trials and gives you some things to consider when deciding whether to take part
A Biosimilar is a type of biologic medication. The term “biosimilar” means that the medication is highly similar to the already approved brand name biologic (“originator” medication)
